Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass

Decisions by industry sponsors to end clinical trials early for commercial reasons have been the subject of controversy. I argue that the principal consideration in assessing these decisions ought to be the way in which the termination would affect the trial’s risk-benefit relationship. If there is...

Full description

Saved in:  
Bibliographic Details
Main Author: Iltis, A. S. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2005
In: Journal of medical ethics
Year: 2005, Volume: 31, Issue: 7, Pages: 410-414
Online Access: Volltext (JSTOR)
Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000naa a22000002 4500
001 181612883X
003 DE-627
005 20220908053413.0
007 cr uuu---uuuuu
008 220908s2005 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.2004.008771  |2 doi 
035 |a (DE-627)181612883X 
035 |a (DE-599)KXP181612883X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Iltis, A. S.  |e VerfasserIn  |4 aut 
245 1 0 |a Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass 
264 1 |c 2005 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Decisions by industry sponsors to end clinical trials early for commercial reasons have been the subject of controversy. I argue that the principal consideration in assessing these decisions ought to be the way in which the termination would affect the trial’s risk-benefit relationship. If there is not yet sufficient benefit to be gained from the study to offset the risks to which participants were exposed and it is expected that important scientific information would be obtained if the trial were continued, early termination constitutes an unethical alteration of the risk−benefit relationship. This violates the grounds on which permission is given to conduct human research, patients consent to participate, and investigators agree to conduct studies. These knowable and avoidable changes in risk-benefit relationship should generally be seen as impermissible. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 31(2005), 7, Seite 410-414  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:31  |g year:2005  |g number:7  |g pages:410-414 
856 |3 Volltext  |u http://www.jstor.org/stable/27719439  |x JSTOR 
856 |u https://jme.bmj.com/content/medethics/31/7/410.full.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [open (via free pdf)] 
856 4 0 |u https://doi.org/10.1136/jme.2004.008771  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/31/7/410.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185582684 
LOK |0 003 DE-627 
LOK |0 004 181612883X 
LOK |0 005 20220908053413 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#564081D2AAB4FE3B79BE55FA842190412B49DFED 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/27719439 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw